Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma

Background: Wixela(®) Inhub(®) is a dry powder inhaler approved as a generic equivalent to Advair(®) Diskus(®) (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at confirming the local (lung) the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Aerosol Med Pulm Drug Deliv
Autors principals: Ng, Dik, Kerwin, Edward M., White, Martha V., Miller, S. David, Haughie, Scott, Ward, Jonathan K., Allan, Richard
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc., publishers 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7133441/
https://ncbi.nlm.nih.gov/pubmed/31634023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jamp.2019.1547
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars